Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients
Year: 2015
Type: article
Study design: Observational Study
Abstract: BACKGROUND: The goal of this work was to assess the safety and efficacy of biologics (ie, tumor necrosis factor-α antagonists and tocilizumab) in patients with Takayasu arteritis. METHODS AND RESULTS: This was a retrospective, multicenter study of the characteristics and outcomes of 49 patients with Takayasu arteritis (80% female; median age, 42 years [20-55 years] treated by tumor necrosis factor-α antagonists [80%] or tocilizumab [20%]) and fulfilling American College of Rheumatology or Ishikawa criteria. Factors associated with complete response were assessed. Eighty-eight percent of patients with Takayasu arteritis were inadequately controlled with or were intolerant to conventional immunosuppressive therapy (median number, 3 [1-5]). Overall response (ie, complete and partial) to biological-targeted treatments at 6 and 12 months was 75% and 83%, respectively. There were significantly lower C-reactive protein levels at the initiation of biological-targeted treatments (22 mg/L [10-46 mg/L] versus 58 mg/L [26-76 mg/L]; P=0.006) and a trend toward fewer immunosuppressants drugs used before biologics (P=0.054) in responders (ie, complete or partial responders) relative to nonresponders to biological-targeted treatments. C-reactive protein levels and daily prednisone dose significantly decreased after 12 months of biological-targeted treatments (30 versus 6 mg/L [P<0.05] and 15 versus 7.5 mg [P<0.05] at baseline and 12 months, respectively). The 3-year relapse-free survival was 90.9% (83.5%-99%) over the biological treatment period compared with 58.7% (43.3%-79.7%; P=0.0025) with disease-modifying antirheumatic drugs. No difference in efficacy was found between tumor necrosis factor-α antagonists and tocilizumab. After a median follow-up of 24 months (2-95 months), 21% of patients experienced adverse effects, with biological-targeted treatments discontinued in 6.6% of cases. CONCLUSION: This nationwide study shows a high efficacy of biological-targeted treatments in refractory patients with Takayasu arteritis with an acceptable safety profile.
Source: Circulation
Authors: Arsene Mekinian, Cloé Comarmond, Mathieu Resche-Rigon, Tristan Mirault, Jean Emmanuel Kahn, Marc Lambert, Jean Sibilia, Antoine Néel, Pascal Cohen, Miguel Hie, Sabine Berthier, Isabelle Marie, Christian Lavigne, Marie Anne Vandenhende, Géraldine Muller, Zahir Amoura, Hervé Devilliers, Sébastien Abad, Mohamed Hamidou, Loïc Guillevin, Robin Dhote, Bertrand Godeau, Emmanuel Messas, Patrice Cacoub, Olivier Fain, David Saadoun
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Keywords: Takayasu arteritis, giant cell arteritis, biologic therapy, tumor necrosis factor inhibitors, tocilizumab, refractory vasculitis, treatment response, C-reactive protein, relapse-free survival, adverse effects, immunosuppressive therapy, disease-modifying antirheumatic drugs, prednisone dose, treatment efficacy and safety
Open Access status: green
OpenAlex ID: W1895630839
